Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
Would you treat a patient with a pancreatic head mass based on common bile duct brushings suggestive of malignancy, with repeated negative EUS biopsy?
Answer from: Medical Oncologist at Community Practice
Yes, I would if everything else is consistent with pancreatic cancer.
Sign In
or
Register
to read more
18784
Related Questions
How do you counsel patients on imaging findings after liver SBRT for HCC, particularly with regard to expectations on timing to tumor resolution?
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
In a patient with unresectable HCC who developed immune-related colitis with the first dose of tremelimumab/durvalumab, would you consider continuing durvalumab alone after resolution of the colitis with steroid treatment?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?